Acupuncture for the Treatment of Insomnia

NCT ID: NCT00855140

Last Updated: 2017-10-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Insomnia is a common and disabling condition associated with psychiatric and medical comorbidities and often persists despite currently available treatments. Acupuncture has been reported to benefit individuals with insomnia and can decrease hyperarousal. This blinded RCT will investigate the impact of a standardized acupuncture protocol on insomnia, daytime symptoms, and hyperarousal.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Insomnia is a common problem that is disabling and that frequently persists despite available medical and behavioral approaches. It is associated significant psychiatric and medical comorbidities and high medical and societal costs. Benzodiazepine receptor agonists (BzRA's) and cognitive behavioral therapies are common treatments, but despite these, insomnia remains a pervasive problem. Complementary and alternative medicine (CAM) treatments are being used widely for the treatment of insomnia, but many of these modalities have sparse research support. There are numerous reports in the Traditional Chinese Medicine (TCM)literature of dramatic benefits of acupuncture for the treatment of insomnia, but carefully designed studies are limited. Insomnia has been associated with hyperarousal and acupuncture has documented effects on autonomics with a shift towards parasympathetic predominance. In consultation with experts in acupuncture and TCM, we developed a protocol for the treatment of insomnia and have used it clinically with good success.

We will be conducting a 3-year exploratory pilot randomized-controlled blinded trial (RCT) of this protocol on 56 adults with insomnia disorder, utilizing a control condition involving placement of placebo needles. We seek to determine the effect size of this acupuncture intervention in comparison to the control condition in preparation for a more definitive study, with the future primary aim to determine if acupuncture is effective and well tolerated in the treatment of insomnia. Measures will include self-report and objective measures of sleep quality and duration including polysomnography (PSG). Secondary-exploratory aims will be to determine the impact of this acupuncture protocol on daytime symptoms of insomnia such as fatigue, anxiety, and depression as well as to explore the impact of acupuncture on self-report and objective measures of hyperarousal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Insomnia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Insomnia Primary insomnia Insomnia disorder Acupuncture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Subjects were unaware of whether they were receiving verum or sham treatment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham acupuncture

Sham acupuncture at non-active acupuncture points, using the Park Sham Device

Group Type PLACEBO_COMPARATOR

Acupuncture

Intervention Type OTHER

Acupuncture, derived from the TCM literature, specific for insomnia

Verum Acupuncture

Acupuncture following a specific TCM-based protocol

Group Type EXPERIMENTAL

Acupuncture

Intervention Type OTHER

Acupuncture, derived from the TCM literature, specific for insomnia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acupuncture

Acupuncture, derived from the TCM literature, specific for insomnia

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ages 18-60;
2. Ability to speak, read, and write English;
3. Insomnia disorder, as defined by RDC, of 3 months or greater duration.

Exclusion Criteria

1. Presence of serious psychiatric Axis I DSM-IV disorders such as bipolar or psychotic disorders-as individuals with conditions may respond differently than insomnia disorder to the acupuncture intervention, potentially confounding the results;
2. Active suicidal ideation or active psychosis, as this may present a concern regarding safety for a subject's participation in this study;
3. Presence of depressive or anxiety disorders of moderate or greater severity based on either HAM-D scores or HAM-A scores of 14 or greater;
4. Presence of unstable medical conditions commonly associated with significant sleep disturbance, e.g. uncompensated congestive heart failure, as this would not be expected to respond to the acupuncture intervention;
5. Presence of other sleep disorder, such as periodic limb movement disorder or sleep apnea, as these conditions would require other medical treatment-this will be based on known history of sleep disorder or findings on screening PSG of apnea-hypopnea index of \> 10 or periodic limb movement index of \>10;
6. Alcohol use \> 14 beverages/week, as this may impact on response to the intervention and assessment measures;
7. Ongoing use of any recreational drugs;
8. Ongoing use of benzodiazepines, prescription hypnotic medication, over-the-counter hypnotic medication, or nutritional supplements with purported hypnotic effects;
9. Ongoing use of other psychotropic medication, such as psychostimulants, or antipsychotics;
10. Caffeine use \> the equivalent of 5 cups of coffee/day;
11. Pregnancy, as the safe use of acupuncture in pregnancy has not been established;
12. Active malignancy, autoimmune condition, or treatment with immunosuppressive drugs;
13. Presence of coagulopathy or use of anticoagulant medication;
14. Active involvement in any psychotherapy or other treatment specifically directed towards insomnia;
15. Prior experience with acupuncture treatment in the last 6 months or prior participation in an acupuncture research study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Center for Complementary and Integrative Health (NCCIH)

NIH

Sponsor Role collaborator

University of Pittsburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ronald M. Glick

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ronald M Glick, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center for Integrative Medicine at UPMC Shadyside

Pittsburgh, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R21AT004429

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R21AT004429-01A1

Identifier Type: NIH

Identifier Source: org_study_id

View Link